Innovative Research from OneOncology at ASH Annual Meeting
Key Highlights
- 25 scientific abstracts highlighting work in lymphoma, leukemia, and multiple myeloma, showcasing the vital role community-based investigators play in blood cancer research.
- Significantly, data indicate that bi-specific antibodies are safely applicable in community practices.
- Research efforts show a promising expansion of CAR-T therapies into aggressive forms of the disease, making strides in treating vulnerable patient groups.
OneOncology, a physician-led platform focused on enhancing independent medical specialty practices, along with the OneOncology Research Network (OneR), proudly spotlight the scientific contributions of its partner practice investigators. Their significant findings will be unveiled at the upcoming American Society of Hematology (ASH) Annual Meeting.
Showcasing Key Research Themes
This year’s presentations at ASH encompass a diverse range of hematologic malignancies. A total of 25 presentations, including seven oral discussions and 18 poster sessions, will emphasize the crucial role that community-based research sites have in fostering innovation across various targeted therapies and clinical trials.
Expanding Access to Innovative Treatments
According to Dr. Ian W. Flinn, Chief Scientific Officer at OneOncology, "These outcomes demonstrate that our affiliated practices are successfully integrating essential research into the communities where patients reside. The studies highlighted at the ASH meeting address complex challenges, such as the operationalization of cellular therapies and bi-specific antibodies, ultimately broadening access for patients who may not typically engage with research opportunities."
Findings of OneR-Affiliated Investigators
- Innovative therapies: Subcutaneous bispecific antibodies are emerging as transformative frontline options.
- Cellular approaches: Ongoing advancements integrate cellular therapies into treatment for aggressive diseases, including those impacting frail populations.
- Next-generation BTK inhibitors: These agents are yielding durable responses among high-risk patient groups.
- Novel agents: First-in-human studies are shaping future treatment paradigms essential for patient care.
- Genomic tools: Profound improvements in disease assessment and care pathways through genomic profiling.
- Guideline contributions: Ongoing studies are helping to refine clinical guidelines and enhance real-world practice.
- Broad participation: OneR sites are actively engaged in earliest-phase and cell therapy research, contributing significantly across the translational research spectrum beyond late-phase trials.
Additional Information and Engagement
A full listing of abstracts and the respective investigators can be accessed directly for more in-depth knowledge. For those interested in interviews with OneR-affiliated researchers during the ASH event, contact is available through the appropriate channels.
About OneOncology
Founded by community physicians for community physicians, OneOncology is on a mission to enhance the lives of individuals affected by cancer and related diseases. The organization aims to allow community medical practices to maintain independence while improving patient access to care in local settings, at lower costs compared to hospital environments. OneOncology supports its network through group purchasing, operational enhancements, clinic growth, and clinical innovation. Currently, their network includes 36 partner practices with over 2,300 providers, collectively serving around 1.5 million patients across more than 645 care sites nationwide. For additional details, visit oneoncology.com or connect on LinkedIn.
Frequently Asked Questions
How many abstracts are being presented at the ASH Annual Meeting?
There are 25 scientific abstracts being presented, covering various topics related to blood cancers.
What kind of therapies are being highlighted in the presentations?
The presentations focus on innovative therapies including bi-specific antibodies, CAR-T therapies, and novel agents in the treatment of hematologic malignancies.
Who is leading OneOncology's research efforts?
Dr. Ian W. Flinn, the Chief Scientific Officer at OneOncology, is overseeing the research initiatives.
How is community involvement significant in this research?
Community involvement is crucial as it ensures that important cancer research reaches patients in their local settings, enhancing accessibility to cutting-edge therapies.
Where can I find more information about the research findings?
Additional information is typically published on OneOncology's website and will be shared at the ASH Annual Meeting.
